A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects
Trial details
- Registry ID
- NCT04880642
- Drugs studied
- C21
TrialRedline tracks 3 clinical trials sponsored by Vicore Pharma AB: 1 Phase 3, 2 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Trial to Investigate Recovery From COVID-19 With C21 in Adult SubjectsNCT04880642 | C21 | Completed | 2022-04-25Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.NCT06588686 | Buloxibutid | Active not recruiting | 2027-05Estimated |
| Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPFNCT04533022 | C21 | Completed | 2024-03-30Actual |
Names as written in the registry records.
NCT06588686 · Vicore Pharma AB
Before: Estimated. After: Actual.
Before: 360 participants (planned). After: 378 participants (actual).
NCT06588686 · Vicore Pharma AB
Before: Recruiting. After: Active not recruiting.